herpes%20simplex%20virus%20infection
HERPES SIMPLEX VIRUS INFECTION
Primary herpes simplex virus (HSV) infection is first infection with either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2.
First episode-non primary infection is infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively.
Recurrent HSV infection results from reactivation of latent virus. It is usually brought about by triggering factors eg UV light, immunosuppression.
Orolabial HSV disease is mostly caused by HSV-1 that occurs most commonly in children <5 years of age. It is transmitted through close contact with individuals who have active viral shedding.
Genital HSV disease is caused by HSV-2 that is the usual cause of herpes genitalis. It typically occurs in adults and transmitted through sexual contact.

Definition

Primary Herpes Simplex Virus (HSV) Infection

  • 1st infection w/ either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2

First Episode - Nonprimary Infection

  • Infection w/ either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively

Recurrent Herpes Simplex Virus (HSV) Infection

  • Results from reactivation of latent virus
  • Usually brought about by triggering factors (eg UV light, immunosuppression, trauma, stress, febrile illness)
  • Less severe & becomes less frequent w/ time
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
02 Nov 2017
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia. 
15 Nov 2017
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Jairia Dela Cruz, 16 Nov 2017
Treatment with a ribavirin-free regimen of coformulated glecaprevir plus pibrentasvir appears to yield a high rate of sustained virologic response in hepatitis C virus-infected patients with advanced chronic kidney disease, while having an acceptable safety profile, according to the EXPEDITION-4 trial.
Roshini Claire Anthony, 17 Nov 2017

Use of the blood infection biomarker procalcitonin as a guide to prescribing antibiotics led to lower antibiotic exposure and side effects, as well as a lower mortality rate in individuals with acute respiratory infections, based on findings of a meta-analysis.